With preclinical/clinical transition being the largest failure risk in CNS therapeutics development, Transpharmation will be revealing new scientific development work at the 2022 HubXchange’s CNS Therapeutics East Coast roundtable meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape. More details about the topics of discussion and event location to follow.
Click on this link to read about hubXchange: https://www.hub-xchange.com/about-us/
AD/PD™ 2022 brings a new look and a new chapter in the history of the AD/PD™ series of conferences. By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now transformed into an annual meeting, with a continuing focus on the advances in science and therapy of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
One of Transpharmation’s scientist, Caoimhe Tyndall will be presenting a poster; 'Assessing the immunogenicity of α-Synuclein oligomers, filaments, and fibrils in a clinically relevant model of synucleinopathy in vitro'. We will make the abstract of this poster available to you nearer the time.
For further information on this event click here: https://adpd.kenes.com/